Xuegong Wang

Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease‐Modifying Antirheumatic Drugs in the Treatment of Moderate‐to‐Severe Rheumatoid Arthritis

Mark C. Genovese, Maria Greenwald, Christine E. Codding et al. · Arthritis & Rheumatology · 2017 · 90 citations

Medicine, Pharmacology, Pharmacotherapy +16

Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study

Robert C. Harland, Göran Klintmalm, Stephen C. Jensik et al. · American Journal of Transplantation · 2019 · 65 citations · Full text

Medicine, Immunology, Pharmacology +14

A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor

Flavio Vincenti, Klemens Budde, Pierre Merville et al. · American Journal of Transplantation · 2018 · 58 citations · Full text

Medicine, Immunology, Infectious Diseases +15

TOLERANCE INDUCED BY DIRECT INOCULATION OF DONOR ANTIGEN INTO THE THYMUS IN LOW AND HIGH RESPONDER RODENTS

Edward J. Alfrey, Xuegong Wang, Larisse Lee et al. · Transplantation · 1995 · 39 citations

Life Sciences, Immunology, Adaptive Immunity +15

A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients

Per Ljungman, Arancha Bermúdez, Aaron C. Logan et al. · EClinicalMedicine · 2021 · 38 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17